{"id":50225,"date":"2022-10-28T16:02:09","date_gmt":"2022-10-28T14:02:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-renal-osteodystrophy-market-research-report-2022-2028-featuring-major-players-amgen-asahi-kasei-and-b-braun-medical-baxter-international-davita-researchandmarkets-com\/"},"modified":"2022-10-28T16:02:09","modified_gmt":"2022-10-28T14:02:09","slug":"global-renal-osteodystrophy-market-research-report-2022-2028-featuring-major-players-amgen-asahi-kasei-and-b-braun-medical-baxter-international-davita-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-renal-osteodystrophy-market-research-report-2022-2028-featuring-major-players-amgen-asahi-kasei-and-b-braun-medical-baxter-international-davita-researchandmarkets-com\/","title":{"rendered":"Global Renal Osteodystrophy Market Research Report 2022-2028 Featuring Major Players – Amgen, Asahi Kasei, and B. Braun Medical, Baxter International, & DaVita – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Renal Osteodystrophy Market Research and Forecast, 2022-2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global renal osteodystrophy market is anticipated to grow at a considerable growth during the forecast period. The factor responsible for the growth of renal osteodystrophy is increasing congenital kidney diseases such as polycystic kidney disease(PKD), Alport syndrome, Goodpasture syndrome, and congenital hypoplasia.\n<\/p>\n

\nMoreover, the rising number of chronic hypertension and atherosclerosis contributes to the growth of the market. According to WHO, in August 2021, an estimated 1.28 billion adults aged 30-79 years globally have hypertension, most (two-thirds) living in low- and middle-income countries. The WHO African Region has the highest prevalence of hypertension at 27%, while the WHO Region of the Americas has the lowest prevalence of hypertension at 18%.\n<\/p>\n

\nThe global renal osteodystrophy market is segmented on the basis on diagnosis method, and treatment. Based on diagnoses method, the market is bifurcated into bone biopsy, and blood test. Based on treatment, the market is bifurcated into hemodialysis, kidney transplantation, medication and parathyroidectomy.\n<\/p>\n

\nBased on diagnosis method, bone biopsy segments is expected to grow at the fastest rate, owing to the growing incidence and prevalence of cancer, rising demand for minimally invasive techniques, and choice of best diagnostics options among others, are the prominent factor driving the growth of the segment in global renal osteodystrophy market.\n<\/p>\n

\nGeographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is the largest in the global renal osteodystrophy market. The market is driven due to the increasing patient pool for cancer, improved coverage of reimbursement, and increasing approvals to new and advanced technology in the Asia-Pacific region.\n<\/p>\n

\nFor instance, in June 2021, Sanwa Kagaku Kenkyusho Co., Ltd., of Japan received marketing authorization approval for UPASITA IV injection syringes for the treatment of secondary hyperparathyroidism in patients on hemodialysis. UPASITA was created by Ajinomoto pharmaceuticals Co., Ltd.\n<\/p>\n

\nThe major companies serving the global renal osteodystrophy market are Amgen Inc., Asahi Kasei Corp., and B. Braun Medical, Baxter International Inc., DaVita Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.\n<\/p>\n

\nFor instance, in August 2021, AstraZeneca K.K. and Ono Pharmaceutical Co. Ltd. announced that Forxiga an inhibitor of sodium-glucose co-transporter 2 received additional approval for the indication of chronic kidney disease with and without type-2 diabetes. This transformational milestone brings great hope to many patients with chronic kidney diseases in Japan.\n<\/p>\n

\nThe Report Covers<\/strong>\n<\/p>\n